Home › NCT07169825
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
RecruitingPhase 4
Who can join
All ages · Men
Full eligibility criteria
Eligibility Criteria * Participants that are approved for Pluvicto therapy and have been identified to have renal complications or compromised marrow function. Renal complication is defined as GFR: 30-50ml/min, creatinine: ULN-twofold ULN; while compromised marrow function is indicated by total WBC 2.5 x 109 L - LLN, or platelet count 75-100 x 109 L. * Participants who agree to be imaged multiple times as defined in the study protocol. Exclusion Criteria * Pluvicto therapy patients without renal or marrow function complications * Participants who do not wish to be imaged multiple times as per the study protocol. * Women and children since this is treatment for prostate cancer.
About the study
To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
What is being tested
- Lu-177 (drug)
- SPECT (other)
Sponsor: M.D. Anderson Cancer Center · Participants: 25 · Started: Mar 30, 2026
Contact the study team
- Guofan Xu, MD · Phone: 713-745-9017
Official record on ClinicalTrials.gov — NCT07169825
Locations in the U.S.
| Texas | MD Anderson Cancer Center, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.